title: Selumetinib increases the efficacy of first-line dacarbazine.
abstract: Selumetinib plus dacarbazine prolongs progression-free survival in BRAF-mutant melanoma.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage*; D003606:Dacarbazine / Q000008:administration & dosage*; D018572:Disease-Free Survival; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality
chemical_list: C517975:AZD 6244; D001562:Benzimidazoles; D003606:Dacarbazine; D048493:Proto-Oncogene Proteins B-raf